Scarica l'app Stockscreener
85.54
0.85%
0.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.82
Aprire:
$84.26
Volume 24 ore:
668.69K
Relative Volume:
0.77
Capitalizzazione di mercato:
$3.89B
Reddito:
$1.33B
Utile/perdita netta:
$97.31M
Rapporto P/E:
42.10
EPS:
2.0317
Flusso di cassa netto:
$260.44M
1 W Prestazione:
+8.58%
1M Prestazione:
+14.05%
6M Prestazione:
+28.32%
1 anno Prestazione:
+15.53%
Intervallo 1D:
$82.75
$85.61
Intervallo di 1 settimana:
$79.35
$85.71
Portata 52W:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
85.58 | 3.63B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Haemonetics Corp (HAE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Haemonetics Corp (HAE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Haemonetics Corp (HAE) Income Statement - TradingKey
Haemonetics Corp (HAE) Balance Sheet - TradingKey
HAE|Haemonetics Corp|Price:80.480|Chg%:+1.700 - TradingKey
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Haemonetics Corp (HAE) Institutional Confidence - TradingKey
Haemonetics Corp (HAE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Haemonetics Corp (HAE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HAE|Haemonetics Corp|Price:78.650| - TradingKey
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies - GlobeNewswire Inc.
HAE|Haemonetics Corp|Price:79.980|Chg%:+1.200 - TradingKey
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Haemonetics (HAE) Q4 2026 Earnings ReportResults, Call & Slides - TipRanks
Haemonetics stock trades steadily as recent earnings highlight blood management growth - Ad-hoc-news.de
Haemonetics stock trades steadily as revenue and earnings grow - Ad-hoc-news.de
Haemonetics (HAE) Could Be 10% Undervalued On Its Margin Expansion Story - simplywall.st
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
HAE Maintained by Mizuho -- Price Target Raised to $90 - GuruFocus
Is Haemonetics Corp (HAE) a Bargain After 3.2% Drop? GF Value Sa - GuruFocus
HAE5817431 Bond Profile — Key Metrics - TradingView
Haemonetics (HAE) Joins Russell Indexes As Investors Ask If The Stock Is Still Undervalued - simplywall.st
HAE stock steadies as Haemonetics focuses on blood and plasma - Ad-hoc-news.de
HAE stock holds steady as investors track Haemonetics' product mix - Ad-hoc-news.de
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $79 - 富途牛牛
Haemonetics sets Aug. 6 call for Q1 2027 results - Stock Titan
Haemonetics (HAE) Analyst Adjusts Price Target Despite Neutral R - GuruFocus
Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter - Ad-hoc-news.de
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation's $210 Million Cash Flow: Is The Transition Working? - Smartkarma
Daily Brief Health Care: Bausch Health Companies, Biodexa Pharmaceuticals, Fortrea Holdings , Haemonetics Corp, Legend Biotech Corp and more - Smartkarma
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers - Ad-hoc-news.de
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE) - simplywall.st
HAE Reiterated by BTIG -- Price Target Maintained at $84 - GuruFocus
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100 - GuruFocus
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $85 - 富途牛牛
Quietly ambitious, Haemonetics NexSys PCS pushes plasma efficiency further - AD HOC NEWS
Why Haemonetics’ NexSys PCS quietly reshapes plasma collection on the clinic floor - AD HOC NEWS
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Loomis Sayles Small Cap Core Portfolio's Haemonetics Corp(HAE) Holding History - GuruFocus
HAE Reiterated by BTIG -- Price Target Maintained at $84.00 - GuruFocus
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 T - GuruFocus
HAE: Upcoming Virtual Meeting Scheduled for June 24 - GuruFocus
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):